Navidea Biopharmaceuticals said it has gathered a sufficient number of participants in its NEO3-06 Phase III trial to do a pre-planned interim analysis of Lymphoseek in patients with head and neck cancer. The analysis will compare the pathological findings on sentinel lymph nodes identified using Lymphoseek with those of lymph nodes removed in a full nodal dissection surgery of the head and neck. Findings from the analysis are expected later this year.

Full Story:
Business Wire

Related Summaries